Unlearn.AI Closes On $12M To Improve Clinical Trials

It is often difficult to find enough patients for clinical trials.

So San Francisco-based Unlearn developed DiGenesis, a machine-learning platform that generates control patient data for clinical studies. Now the company has secured a $12 million Series A financing.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Digital Twins: A Tool for Risk Mitigation in the Era of COVID-19

Blog

CB Insights 2020 Digital Health 150: Unlearn.AI named in List of Most Innovative Digital Health Startups

Blog

Embracing Innovation to Move Forward

At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.
Unlearn is thrilled to be recognized as a contributing member of the international community of pioneers in health.
In what ways can we mitigate risk and apply innovative solutions to unstable trials in the wake of COVID-19?